| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6517847 | BAUSCH | Topical gel delivery system |
Aug, 2020
(3 years ago) | |
| US10478502 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(7 years from now) | |
| US11839656 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(7 years from now) | |
| US8809307 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(7 years from now) | |
Bryhali is owned by Bausch.
Bryhali contains Halobetasol Propionate.
Bryhali has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Bryhali are:
- US6517847
Bryhali was authorised for market use on 06 November, 2018.
Bryhali is available in lotion;topical dosage forms.
Bryhali can be used as topical treatment of plaque psoriasis in adults.
The generics of Bryhali are possible to be released after 02 November, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 06, 2021 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 06 November, 2018
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION;TOPICAL
How can I launch a generic of BRYHALI before it's drug patent expiration?
More Information on Dosage
BRYHALI family patents
